- Trials with a EudraCT protocol (32)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
32 result(s) found for: AL+Amyloidosis.
Displaying page 1 of 2.
EudraCT Number: 2017-002210-31 | Sponsor Protocol Number: AC-012-EU | Start Date*: 2019-05-31 |
Sponsor Name:Amyloid Center - Biotechnology Research Laboratories Policlinico San Matteo | ||
Full Title: A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy | ||
Medical condition: Light chain (AL) amyloidosis is a protein conformational disease, caused by a small bone marrow plasma cell clone producing light chains (LCs) that undergo conformational changes, aggregate and d... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003865-11 | Sponsor Protocol Number: NEOD001-CL002 | Start Date*: 2015-11-27 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chai... | |||||||||||||
Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended) GR (Completed) PL (Prematurely Ended) DK (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004318-14 | Sponsor Protocol Number: NEOD001-201 | Start Date*: 2016-06-13 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction | |||||||||||||
Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Completed) GR (Completed) ES (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001787-22 | Sponsor Protocol Number: AC-007-IT | Start Date*: 2012-05-02 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: An open-label, phase II study of Pomalidomide and Dexamethasone (PDex) for previously treated patients with AL amyloidosis | |||||||||||||
Medical condition: Previously treated AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000489-50 | Sponsor Protocol Number: AC-009-IT | Start Date*: 2017-10-03 | |||||||||||
Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO | |||||||||||||
Full Title: A Phase II, Single Arm, Open Label, Efficacy and Safety Study of NEOD001 in Subjects with Light Chain (AL) Amyloidosis with Hepatic Involvement | |||||||||||||
Medical condition: AL amyloidosis with hepatic involvement | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000037-14 | Sponsor Protocol Number: NEOD001-301 | Start Date*: 2021-09-01 | |||||||||||
Sponsor Name:Prothena Biosciences Limited | |||||||||||||
Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with ... | |||||||||||||
Medical condition: AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, a... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) HU (Ongoing) DE (Ongoing) PT (Ongoing) PL (Ongoing) ES (Ongoing) GR (Ongoing) NL (Ongoing) IT (Ongoing) IE (Ongoing) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021445-42 | Sponsor Protocol Number: HO104 | Start Date*: 2011-08-31 | |||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||
Full Title: A multicenter, phase II study of bortezomib and dexamethasone as induction treatment followed by high dose melphalan (HDM) and autologous stem cell transplantation (SCT) in patients with de novo am... | |||||||||||||
Medical condition: AL Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-007082-36 | Sponsor Protocol Number: RV178 | Start Date*: 2007-10-16 |
Sponsor Name:Hellenic Oncology Cooperative Group | ||
Full Title: A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis | ||
Medical condition: Primary (AL) amyloidosis in untreated patients or patientsw who have failed prior treatments | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-007125-39 | Sponsor Protocol Number: LeBenD | Start Date*: 2011-04-19 |
Sponsor Name:Klinik f. Innere Med., Fachabteilung Hämatologie | ||
Full Title: A phase I-II trial of lenalidomide, bendamustin and dexamethasone in the treatment of patients with systemic AL-amyloidosis and ineligible for stem cell transplantation | ||
Medical condition: AL-amyloidose | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-001405-41 | Sponsor Protocol Number: GMIHO-005/2007 (191063) | Start Date*: 2008-10-24 |
Sponsor Name:GMIHO mbH | ||
Full Title: A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) | ||
Medical condition: AL amyloidosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002231-18 | Sponsor Protocol Number: RMHCAN1104 | Start Date*: 2015-12-01 | |||||||||||
Sponsor Name:University Southampton Hospital NHS Foundation Trust | |||||||||||||
Full Title: A Phase I/IIa Study of Targeted Radiotherapy alone for Stem Cell Transplant Conditioning in Systemic AL Amyloidosis | |||||||||||||
Medical condition: AL-Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002639-48 | Sponsor Protocol Number: 54767414AMY2009 | Start Date*: 2022-07-25 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis | |||||||||||||
Medical condition: Amyloid Light Chain Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) IT (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002761-19 | Sponsor Protocol Number: OP201 | Start Date*: 2019-10-21 | |||||||||||
Sponsor Name:Oncopeptides AB | |||||||||||||
Full Title: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy | |||||||||||||
Medical condition: Patients with AL Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) NO (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) GR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001737-27 | Sponsor Protocol Number: 54767414AMY3001 | Start Date*: 2018-04-16 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnos... | |||||||||||||
Medical condition: AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Ongoing) SE (Ongoing) ES (Ongoing) HU (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) DK (Ongoing) PL (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004254-28 | Sponsor Protocol Number: CAEL101-301 | Start Date*: 2021-01-07 | |||||||||||
Sponsor Name:Caelum Biosciences, Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dysc... | |||||||||||||
Medical condition: stage IIIb cardiac AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) PL (Ongoing) BE (Ongoing) AT (Ongoing) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000713-32 | Sponsor Protocol Number: CAEL101-302 | Start Date*: 2020-12-23 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dysc... | |||||||||||||
Medical condition: stage IIIa cardiac AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) PL (Ongoing) BE (Ongoing) AT (Ongoing) CZ (Ongoing) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004664-18 | Sponsor Protocol Number: NEOD001-OLE251 | Start Date*: 2017-08-08 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO) | |||||||||||||
Medical condition: The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who completed Study NEOD001 201 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006037-13 | Sponsor Protocol Number: AC-003-IT | Start Date*: 2008-02-21 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis | |||||||||||||
Medical condition: amyloidosis AL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005468-10 | Sponsor Protocol Number: C16011 | Start Date*: 2012-11-28 |
Sponsor Name:Millennium Pharmaceuticals, Inc. | ||
Full Title: A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refra... | ||
Medical condition: Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) NL (Completed) GB (Prematurely Ended) IT (Ongoing) GR (Completed) ES (Prematurely Ended) DK (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001962-13 | Sponsor Protocol Number: AC-016-IT | Start Date*: 2021-01-13 | |||||||||||
Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO | |||||||||||||
Full Title: A multi-center open label phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis | |||||||||||||
Medical condition: AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
